IL-4 epigenetically reprograms CART19-28ζ cells to drive dysfunction

作者
Carli M. Stewart,Mehrdad Hefazi,Makena Rodriguez,Grace E. DeFranco,Sara Foote,Brooke L. Kimball,Long Mai,Truc Huynh,Elizabeth L. Siegler,Jennifer Meyer Feigin,Kun Yun,Dominic A. Skeele,Sophia Y. Goldberg,Ateka Saleh,Olivia L. Sirpilla,İsmail Can,Hong Xia,Omar Gutierrez Ruiz,Ekene J. Ogbodo,Sameer Ashok Parikh
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 2338-2338
标识
DOI:10.1182/blood-2025-2338
摘要

Abstract Recent studies have highlighted the important but pleiotropic role of IL-4 in response to chimeric antigen receptor T (CART) cell therapy. IL-4 was identified as a regulator of dysfunction in CD19-targeting CART cells with a CD28 costimulatory domain (CART19-28ζ) through a genome-wide CRISPR knockout screen as well as RNA and ATAC sequencing of baseline and exhausted healthy donor CART19-28ζ cells and pre-infusion CART19-28ζ cell products from responders and non-responders in the ZUMA-1 trial (Stewart et al, Nat Commun., 2024). However, interrogation of a single-cell atlas fromactivated pre-infusion CART cell products from patients with acute lymphoblastic leukemia revealed a beneficial role for IL-4 and other type 2 cytokines in the promotion of long-term response (Bai et al, Nature, 2024). In this report, we aim to further understand how IL-4 can be detrimental to CART cell therapy. To study the regulation of CART19-28ζ cells by IL-4, we performed RNA sequencing on CART19-28ζ cells that were stimulated with CD19+target cells in the presence of either 20 ng/mL hrIL-4 or diluent for 24 hours, one week, or two weeks in an in vitro model for exhaustion as previously described (Stewart et al, Nat Commun., 2024). We observed that hrIL-4 treatment drove the development of a distinct transcriptomic profile after chronic stimulation for one week (up genes = 3253 and down genes = 3645) or two weeks (up genes = 6435 and down genes = 6224) but not following 24 hours of activation (up genes = 0 and down genes = 0). Gene set enrichment analysis on the differentially expressed genes following two weeks of chronic stimulation showed that hrIL-4 treatment pushes CART cells to a more exhausted and less naïve phenotype (FDR = 0.015) and leads to a broad downregulation in cytokine signaling (FDR = 0.012). To investigate transcription factors associated with IL-4-induced CART cell dysfunction, we used BETA analysis with publicly available transcription factor binding sites for STAT6, GATA3, and EOMES and our differential expression data. EOMES (p = 0.039), but not STAT6 (p = 0.999) nor GATA3 (p = 0.999) significantly regulated the differentially expressed genes. In support of these findings, the addition of hrIL-4 also significantly upregulated EOMES expression after one (p < 0.0001) and two (p < 0.0001) weeks of chronic stimulation and downregulated the expression of TBX21 (p < 0.0001), a binding competitor of EOMES, following two weeks of chronic stimulation. To evaluate if EOMES is critical for IL-4-induced CART cell dysfunction, we treated either control or EOMES CRISPR knockdown CART cells with 20ng/mL hrIL-4 during chronic stimulation. EOMES knockdown reduced IL-4-induced CART19-28ζ cell dysfunction as seen by an increase in antigen-specific expansion (p = 0.046) and an increase in cytokine production including IL-2 (p < 0.0001), TNF-α (p = 0.006), and IFN-γ (p = 0.020). Having identified that EOMES is at least partially responsible for IL-4-induced CART cell dysfunction, we evaluated EOMES binding sites in human CART19-28ζ cells with CUT&RUN sequencing. Our analysis revealed EOMES binding at hypersensitivity site 2 (HS2) in the IL-4 locus which, in a previous study, was more accessible in both exhausted healthy donor CART19-28ζ cells and pre-infusion CART cell products from non-responders in the ZUMA-1 clinical trial (Stewart et al, Nat Commun., 2024). To determine how HS2 can impact CART cell functions, we generated CART19-28ζ cells from either wildtype (HS2+/+) or HS2-deleted (HS2-/-) murine T-cells and tested them in a syngeneic model of lymphoma generated by engrafting C57BL6 mice with luciferase+ TBL12 cells (1x106, tail vein injection on Day -3) following preconditioning (250mg/kg cyclophosphamide, intraperitoneal injection on Day -4). Following randomization of mice via tumor burden (n = 5 per group), mice were treated with either HS2+/+ or HS2-/- CART19-28ζ cells (1x106 cells, tail vein injection). In this model, HS2-/- CART cells showed enhanced expansion (p = 0.022), increased anti-tumor activity (p = 0.018), and improved overall survival (p = 0.003). Together, our study shows that IL-4 induces a distinct cellular fate in CART19-28ζ cells in the presence of chronic antigen-specific stimulation at least partially through the upregulation of EOMES. Further, the epigenetic regulation of CART cells by the IL-4 enhancer HS2 can significantly influence CART cell activity, and deletion of HS2 can improve CART cell therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
DW的应助被momo采纳,获得10
刚刚
大胆笑翠完成签到,获得积分10
刚刚
大聪明完成签到,获得积分10
刚刚
刚刚
刚刚
呆萌彩虹完成签到,获得积分10
刚刚
1秒前
1秒前
guo7700完成签到,获得积分10
1秒前
果小镁完成签到,获得积分10
1秒前
Lucy11grandma完成签到,获得积分10
2秒前
万霖发布了新的文献求助10
2秒前
温暖元柏发布了新的文献求助10
2秒前
菜菜的应助被星空采纳,获得10
2秒前
2秒前
2秒前
张靓靓发布了新的文献求助10
3秒前
molihuakai的应助被111采纳,获得10
3秒前
堪灵槐完成签到,获得积分10
4秒前
4秒前
hgf发布了新的文献求助30
4秒前
yyyy发布了新的文献求助10
4秒前
一个张张包完成签到,获得积分10
4秒前
动听翠萱完成签到,获得积分10
5秒前
04d的应助被正直的黑猫采纳,获得10
5秒前
如意元霜发布了新的文献求助10
6秒前
6秒前
QQ发布了新的文献求助10
6秒前
weddcf发布了新的文献求助10
7秒前
7秒前
cb666发布了新的文献求助10
7秒前
重要无招完成签到,获得积分10
7秒前
7秒前
lulufighting完成签到,获得积分10
8秒前
1820发布了新的文献求助10
8秒前
FF完成签到 ,获得积分10
8秒前
8秒前
lya完成签到,获得积分10
8秒前
yhy完成签到,获得积分10
8秒前
七听的应助被六六采纳,获得30
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180617
求助须知:如何正确求助?哪些是违规求助? 9570702
关于积分的说明 21813868
捐赠科研通 7776860
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557571
邀请新用户注册赠送积分活动 2479253